63
Participants
Start Date
July 31, 2002
Primary Completion Date
May 31, 2009
Study Completion Date
May 31, 2009
Pegylated Liposomal Doxorubicine
In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
University of Regensburg, Department of Neurology, Regensburg
Collaborators (1)
Essex Pharma Germany
OTHER
University of Regensburg
OTHER